Corporate Learning Technology Company Attensi Announces $26m Investment From Lugard Road Capital, DX Ventures, and Viking Venture for Global Expansion
8.4.2021 10:00:00 EEST | Business Wire | Press release
Corporate Learning and Development (L&D) technology innovator Attensi is executing its plans for global expansion after raising $26m from New York-based Lugard Road Capital, DX Ventures, and existing share holder Viking Venture. The investment follows several years of rapid growth for the company, during which Attensi has recorded a 63% CAGR in annual recurring revenue and executed projects for a wide range of international blue-chip customers. The new funding will be used by Attensi to extend its presence in North America and Europe and to expand upon its leading product suite and technology platform in gamified simulations.
“Attensi solutions enable organizations to upskill their people faster, consistently, at scale, with results beyond the capabilities of traditional methods like e-learning, video, or classroom training. With gamified simulation training, we have combined the best of workplace psychology with our expertise in simulations and gamification to create a new category of training solutions. Our gamified simulations create significant real-world impact on companies’ core business metrics,” said Attensi Co-Founder and Co-CEO, Trond Aas. “This funding round enables our ambitious growth plans. With Lugard Road Capital we are bringing in a major US investor with experience of growing SaaS companies into global brands.”
With a client base that includes Daimler Mercedes Benz, Circle K, Equinor, BCG, and ASDA, Attensi uses a fusion of technology from the world of video gaming and insights from workplace psychology to train people via immersive, 3D simulations of their workplace and work processes. At the end of last year, the company announced plans to further develop its technology platform and enter new markets by the end of 2021. The fundraise from Lugard Road Capital, DX Ventures, and Viking Venture represents an acceleration of these plans.
Anne-Lise Waal, CTO and Co-CEO at Attensi said: “This is exciting news for everyone at Attensi. With the Attensi Technology Platform users across the globe can create high-end gamified solutions with our powerful no-code toolset. This investment will be instrumental in further expanding our cloud native SaaS platform and product suite. The Attensi Technology Platform will equip companies across all sectors to deliver on the challenge of continuous development and upskilling of their workforce. Our current plans for organizational expansion will see our staff count grow rapidly from the current level of 120 to well over 200.”
Doug Friedman, partner at Lugard Road Capital, said: “We could not be more excited to be investing in the Attensi team as they work to forever change and improve corporate learning and development through their Attensi solutions.”
Duncan McIntyre, Managing Director at DX Ventures, said: “Learning and development opportunities are becoming a decisive competitive factor to improve performance, attract and retain talent. We are thrilled to support Attensi to achieve its mission to make corporate training more effective and engaging.”
Eivind Bergsmyr, partner at Viking Venture, commented: “It’s been exciting to see the rapid growth and impressive development driven by the ability to bring in global top brands as customers during our time as investor in Attensi. This capital raise expands the investor universe with investors we know well from other Viking Venture portfolio companies and allows Attensi to continue its global expansion at increased pace.”
Established in 2012, Attensi has delivered gamified simulation training in more than 100 countries in 20 languages. Attensi solutions are used to simulate human interactions and work processes, including interpersonal ‘soft skills’, leadership training, use of IT-systems and any form of staff certification. Whether on mobile, desktop, or VR, Attensi’s gamified simulation approach enables organizations to upskill their people effectively, consistently, at scale, with all the data required to track impact on KPIs.
Attensi clients are corporate blue-chip companies in health care, pharmaceutical, financial services, professional services, retail, hospitality, manufacturing, shipping, offshore and transport, as well as public and third sectors. The company’s total revenue annual run-rate is currently $12m, and is headquartered in Oslo, Norway, with offices in London, UK, and Palo Alto, USA.
Pareto was engaged as Global Coordinator for the equity issue. GCA Altium is acting as the Global Financial Advisor to the company. Thommessen acted as the legal advisor in the transaction.
ENDS
Notes to editors:
About Attensi
Driven by the best of psychology, learning, and gaming, Attensi gamified simulation training engages your people with measurable impact on your KPIs. Whether on mobile, desktop, or VR, Attensi solutions empower people to learn new skills and behaviours in a fun, engaging way. The results enable organizations to excel in staff training, onboarding, and retention.
Attensi has delivered gamified simulation training in more than 100 countries, in 20 languages, and employs over 100 staff. Attensi is headquartered in Oslo, Norway, with offices in London, and Palo Alto, USA.
About Viking Venture
Viking Venture is the leading Nordic Software investor with more than NOK 3 billion under management. Since 2001, Viking Venture has invested in more than 50 Nordic companies with a particular focus on scaling Business-to-business (B2B) Software-as-a-Service (SaaS) companies. Viking Venture has been the lead investor of Attensi since 2018.
About Lugard Road Capital
Lugard Road Capital is a multi-billion-dollar global investment fund primarily focused on public and private companies in the Internet, software, consumer, and technology sectors.
About DX Ventures
DX Ventures is a venture capital fund backed by Delivery Hero. The fund’s mission is to support the next generation of founder-led companies that are disrupting some of the most rapidly changing industries around the world. The investment philosophy is centered on building long term partnerships with founders to provide support throughout the lifecycle and actively create value.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005063/en/
Contact information
Media:
Steve Maybury | steve@opr.co.uk | +44 (0)7985774743
Aranda Rahbarkouhi | aranda@opr.co.uk | +44 (0)7807009347
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off
PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release
Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N
AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 09:00:00 EEST | Press release
AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To
Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release
Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/ Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
